Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Gains from Investment Securities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Gains from Investment Securities for 2 consecutive years, with $12.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities rose 82.81% to $12.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $12.7 million, a 82.81% increase, with the full-year FY2024 number at $9.7 million, up 9611.07% from a year prior.
  • Gains from Investment Securities was $12.7 million for Q2 2025 at Pyxis Oncology, up from -$136000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.7 million in Q2 2025 to a low of -$136000.0 in Q4 2024.